Science & Enterprise subscription

Follow us on Twitter

  • https://t.co/j6Bc09NhlE
    about 24 hours ago
  • A new analysis from technology intelligence company GlobaData shows the top 2 enterprises attracting venture financ… https://t.co/Qfo4gwNJqW
    about 2 days ago
  • New post on Science and Enterprise: Infographic – Germany Beats U.K. in Top Venture Funds https://t.co/IdlaDYgl9U #Science #Business
    about 2 days ago
  • New contributed post on Science and Enterprise: https://t.co/sGLg6tmIwx Protecting A Modern Agricultural Business
    about 2 days ago
  • An engineering-psychology team is developing a system connecting virtual reality with brain signals in real time t… https://t.co/mF081BrzQX
    about 3 days ago

Please share Science & Enterprise

RSS
Follow by Email
Facebook
Facebook
Google+
Twitter
Visit Us
LinkedIn
INSTAGRAM

Infectious Disease Diagnostics Company Lands Series B Funds

MRSA bacteria (CDC)

Scanning electron micrograph image of MRSA bacteria (Janice Haney Carr, Centers for Disease Control and Prevention)

Molecular Detection Inc. in Wayne, Pennsylvania, a company developing tests for diagnosing infectious diseases, says it has completed a new $1.9 million round of series B financing, the second funding installment after initial start-up. All existing investors, says the company, took part in the round, including MentorTech Ventures, Robin Hood Ventures, Elm Spring Holdings, and the Mid-Atlantic Angel Group.

Molecular Detection’s technology uses polymerase chain reaction (PCR) testing based on DNA analysis to detect pathogens at extremely low target concentrations in samples. The company says its tests can be done in real time without the daily reagent preparation or cold storage usually required for PCR tests. The tests also return results with greater sensitivity and specificity, thus reducing rates of false positives and negatives.

The company anticipates the funds will be used to advance its MRSA detection panel and to develop new molecular diagnostic panels for the detection of sepsis and gastrointestinal (GI) infections in hospitalized patients. The Detect-Ready MRSA Panel is approved and available in Europe, Australia, and Israel for the detection of MRSA (methicillin-resistant Staphylococcus aureus) and MSSA (methicillin-sensitive S. aureus) pathogens. It has not yet been approved in the U.S.

Molecular Detection says its sepsis test panel is designed to pinpoint the source of the underlying infection and allow treatment to begin as soon as possible. The gastrointestinal panel aims to be the first that can quickly distinguish the source of serious GI infections in hospitalized patients. The company plans to introduce these tests in Europe later this year.

Read more:

*     *     *

Please share Science & Enterprise ...

1 comment to Infectious Disease Diagnostics Company Lands Series B Funds